We don't see that this trend will stop any time soon, and we believe that the company should be avoided at all costs as a result of its frivolous spend and impending liquidity crunch.ĭata by YCharts Upcoming Political HeadwindsĪurora Cannabis was one of the beneficiaries of the change in political climate in 2020. Regardless of the potential synergies through the acquisition, we find that the cash burn in addition to constant acquisitions are not recipes for success when the company's fundamentals continue to decline. Just recently, the company announced a major acquisition at a price tag of ~$45 million CAD in cash. As seen below, the diluted shares outstanding for ACB has soared as a result of various acquisitions and financing needs. We believe given management's history, we find it likely that the management will continue to keep the business afloat through dilutive actions and tapping into the debt markets, which will only further add debt to the unprofitable business. Given the liabilities and the negative earnings, liquidity is risk of the utmost issue, and it is unclear how management plans to navigate through this problem. In that same time frame, the company reported that there's $332.4 million CAD in cash and cash equivalents, which is substantially below the pending commitments in the next few years. In the most recent FY 2021 financial report, the company outlines that ~$494 million CAD are liabilities that are payable between one and three years. The poor financial performance should immediately be a red flag to investors, and we believe that there is no immediate catalyst to turn this stock around anytime soon.įor a company with such large losses, it is not hard to find that the company is exposed to major liquidity issues. These losses are astronomical, given that the cumulative losses are now 10x the current market capitalization of the company. In addition, the company has reported a loss of $1 billion CAD in the recent quarter, and according to a report, the recent quarter increased the cumulative net losses of the company to roughly $5.3 billion CAD since 2015. For the recent quarter, revenue has declined 9% YoY and has declined 17% QoQ. For a growth stock name, the company has actually seen its revenue decline over the past few years, even as the company aggressively acquired competitors. The company is still down ~80% from its 52-week high of $8.69 and the stock price is correlated with the revenue decline. ![]() The company now has a valuation of less than $500 million CAD.ĭata by YCharts Abysmal Performance and ReturnsĪurora Cannabis has had poor financial performance in line with the poor stock price performance in the same time frame. ![]() The stock has had abysmal return for investors, and the stock trades at around $1.675 compared to its historic high above $120 per share only a few years ago. These brands create cannabis products for consumer and medical consumption. ![]() Aurora operates a network of subsidiaries related to the cannabis industry, and the company owns numerous brands, such as San Rafael '71, Daily Special, CanniMed, Whistler Cannabis Co., and more. Company OverviewĪurora Cannabis is a cannabis growing company based in Edmonton, Canada. We believe that liquidity issues and an unfavorable political environment in the United States will continue to drive this stock price lower over the coming years. The company has historically reported poor financial results despite major acquisitions, and the company is burning through cash rapidly as loan commitments are coming due. ![]() With the recent acquisition, Aurora Cannabis ( NASDAQ: ACB) is even more of a stock for investors to avoid.
0 Comments
Leave a Reply. |